Influence of Natural Polysaccharides on Intestinal Microbiota in Inflammatory Bowel Diseases: An Overview

被引:14
|
作者
Li, Qi [1 ]
Li, Linyan [1 ]
Li, Qiqiong [2 ]
Wang, Junqiao [1 ]
Nie, Shaoping [1 ]
Xie, Mingyong [1 ]
机构
[1] Nanchang Univ, State Key Lab Food Sci & Technol, China Canada Joint Lab Food Sci & Technol Nanchan, Key Lab Bioact Polysaccharides Jiangxi Prov, Nanchang 330047, Jiangxi, Peoples R China
[2] Univ Ghent, Fac Biosci Engn, Ctr Microbial Ecol & Technol CMET, B-9000 Ghent, Belgium
关键词
polysaccharides; inflammatory bowel disease; intestinal microbiota; intestinal immunity; short-chain fatty acids; INDUCED ULCERATIVE-COLITIS; CHAIN FATTY-ACIDS; GUT MICROBIOTA; BUTYRATE; BARRIER; HEALTH; DIFFERENTIATION; HOMEOSTASIS; MODULATION; RECEPTOR;
D O I
10.3390/foods11081084
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The incidence of inflammatory bowel disease (IBD) has increased in recent years. Considering the potential side effects of conventional drugs, safe and efficient treatment methods for IBD are required urgently. Natural polysaccharides (NPs) have attracted considerable attention as potential therapeutic agents for IBD owing to their high efficiency, low toxicity, and wide range of biological activities. Intestinal microbiota and their fermentative products, mainly short-chain fatty acids (SCFAs), are thought to mediate the effect of NPs in IBDs. This review explores the beneficial effects of NPs on IBD, with a special focus on the role of intestinal microbes. Intestinal microbiota exert alleviation effects via various mechanisms, such as increasing the intestinal immunity, anti-inflammatory activities, and intestinal barrier protection via microbiota-dependent and microbiota-independent strategies. The aim of this paper was to document evidence of NP-intestinal microbiota-associated IBD prevention, which would be helpful for guidance in the treatment and management of IBD.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Role of the microbiota in inflammatory bowel diseases
    Nagalingam, Nabeetha A.
    Lynch, Susan V.
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (05) : 968 - 980
  • [22] The gut microbiota and inflammatory bowel diseases
    Miyoshi, Jun
    Chang, Eugene B.
    TRANSLATIONAL RESEARCH, 2017, 179 : 38 - 48
  • [23] Overview of Biosimilars in Inflammatory Bowel Diseases
    Feagins, Linda A.
    Gold, Stephanie
    Steinlauf, Adam F.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (02): : 229 - 232
  • [24] Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease
    Weingarden, Alexa R.
    Vaughn, Byron P.
    GUT MICROBES, 2017, 8 (03) : 238 - 252
  • [26] Characterization of small intestinal stoma microbiota in patients with colorectal cancer and inflammatory bowel diseases
    Yilmaz, Bahtiyar
    Fuhrer, Tobias
    Morgenthaler, Deborah
    Krupka, Niklas
    Spari, Daniel
    Candinas, Daniel
    Misselwitz, Benjamin
    Beldi, Guido
    Sauer, Uwe
    Macpherson, Andrew J.
    SWISS MEDICAL WEEKLY, 2022, 152 : 3S - 3S
  • [27] The role of the intestinal microbiota in the aetiology of inflammatory bowel diseases and the impact of Helicobacter pylori infection
    Castano-Rodriguez, N.
    Popple, G.
    Kaakoush, N. O.
    Lee, W.
    Mitchell, H. M.
    HELICOBACTER, 2017, 22
  • [28] Inflammatory Bowel Diseases: The Role of Gut Microbiota
    De Musis, Cristiana
    Granata, Lucia
    Dallio, Marcello
    Miranda, Agnese
    Gravina, Antonietta G.
    Romano, Marco
    CURRENT PHARMACEUTICAL DESIGN, 2020, 26 (25) : 2951 - 2961
  • [29] Inflammatory Bowel Diseases: Microbiota Versus the Barrier
    Damman, Christopher
    Surawicz, Christina M.
    PRACTICAL GASTROENTEROLOGY, 2014, 38 (05) : 48 - 48
  • [30] The influence of microbiota on ferroptosis in intestinal diseases
    Yao, Ting
    Li, Lanjuan
    GUT MICROBES, 2023, 15 (02)